XOMA Corp
NASDAQ:XOMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hayward Holdings Inc
NYSE:HAYW
|
US |
XOMA Corp
Other Current Assets
XOMA Corp
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
XOMA Corp
NASDAQ:XOMA
|
Other Current Assets
$6.3m
|
CAGR 3-Years
85%
|
CAGR 5-Years
26%
|
CAGR 10-Years
13%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$6.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
$4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
15%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$4.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$853.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
23%
|
CAGR 10-Years
21%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$1.2B
|
CAGR 3-Years
43%
|
CAGR 5-Years
50%
|
CAGR 10-Years
22%
|
|
XOMA Corp
Glance View
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.
See Also
What is XOMA Corp's Other Current Assets?
Other Current Assets
6.3m
USD
Based on the financial report for Dec 31, 2025, XOMA Corp's Other Current Assets amounts to 6.3m USD.
What is XOMA Corp's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
13%
Over the last year, the Other Current Assets growth was 85%. The average annual Other Current Assets growth rates for XOMA Corp have been 85% over the past three years , 26% over the past five years , and 13% over the past ten years .
